ArticleBMC pulmonary medicine2026
The diagnosis and prognosis role of miR-155 in neonatal acute respiratory distress syndrome.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal acute respiratory distress syndrome (NARDS) can cause respiratory failure in newborns and even pose a threat to their lives, causing a heavy financial burden on families.
aimThis study aims to explore the potential role of miR-155 as a diagnostic marker and prognostic predictor for NARDS.
methodsThis study included 100 non-NARDS newborns and 100 NARDS newborns. The plasma miR-155 expression was measured by RT-qPCR. The ROC curve was used to analyze the diagnostic efficacy of miR-155 alone and the combined diagnostic efficacy of PT, APTT, FIB, and CRP. The correlation between clinical indicators and miR-155 expression was analyzed by the chi-square test. The general clinical information of NARDS neonates with different severity degrees and prognosis was compared. Multivariate logistic regression was used to identify the risk factors for NARDS.
resultsThe plasma miR-155 level was elevated in NARDS newborns. miR-155 may serve as a promising biomarker in the diagnosis of NARDS. The value of the multi-factor combined diagnosis was significantly improved. 1-minute Apgar score, PT, APTT, and CRP level were statistically related to the miR-155 expression. Abnormal FIB level and the miR-155 expression were independent risk factors for NARDS. The more severe NARDS newborns have poorer coagulation function, stronger inflammatory response, and higher miR-155 level. A higher level of miR-155 was observed in NARDS newborns with a poorer prognosis.
conclusionThe plasma miR-155 level is upregulated in NARDS, and miR-155 may be a potential diagnostic marker for NARDS. NARDS newborns with miR-155 high expression have a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.